The UK’s National Institute for Clinical Excellence (NICE) voted down a recommendation for Gilead Sciences’ chemotherapy drug aimed at triple-negative breast cancer, but approved Merck KGaA’s Bavencio (avelumab), which fought its way back into the agency’s good graces after stakeholders launched a letter-writing campaign and the company lowered its cost.
Source: Drug Industry Daily